Daito Pharmaceutical Co Ltd

Daito Pharmaceutical maintains a conservative capital structure with a debt-to-equity ratio of 0.23, indicating limited leverage and a strong equity base. The company's liquidity position is characterized by a current ratio of 2.45, suggesting it can cover its short-term obligations comfortably. However, the company reported negative net cash of -9,810 million JPY (cash and equivalents of 2,207 million JPY minus long-term debt of 11,885 million JPY), which raises concerns about its ability to fund operations without external financing. Profitability metrics show a return on equity (ROE) of 3.67% and a return on assets (ROA) of 2.45%, both below the industry median for pharmaceutical firms. The company's operating margin is 4.86% (operating income of 2,463 million JPY on revenue of 50,643 million JPY), which is modest compared to peers. The net profit margin of 3.77% (net income of 1,909 million JPY) further highlights the company's limited profitability relative to its revenue base. Geographically, Daito Pharmaceutical's revenue is concentrated in Japan, with no disclosed international segments. The company's exposure to a single market increases its vulnerability to domestic regulatory changes and economic fluctuations. There are no disclosed revenue segments, so it is unclear whether the company operates in multiple therapeutic areas or product lines. The company's growth trajectory is mixed. While revenue for the latest period is reported at 50,643 million JPY, there is no historical data provided to assess year-over-year growth. The free cash flow is negative at -1,930 million JPY, driven by capital expenditures of -7,030 million JPY, which suggests the company is investing in long-term projects but may need to secure additional financing to sustain operations. Risk factors include liquidity concerns due to negative net cash and the potential for dilution, although the risk of dilution is currently assessed as low. The company has not issued new shares recently, and there is no indication of a pending equity offering. However, the negative free cash flow and high capital expenditures may necessitate future financing, which could lead to share dilution. Recent events include analyst price targets that are uniformly set at 1,500 JPY, with a mean recommendation of 3.00 (Hold). There are no strong buy or buy recommendations, indicating a cautious outlook from analysts. No recent filings or transcripts are provided to assess management commentary or strategic direction.